Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

Leukemia volume 19, pages 1729–1738 (2005)Cite this article

Abstract

Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its pathogenesis have identified signaling pathways that have become potential therapeutic targets. It has clearly been established that intracellular regulatory proteins and interactions between malignant plasma cells and the bone marrow microenvironment play an important role in their survival and drug resistance. Several new agents associated with molecular targets are currently being investigated to design new treatment strategies aimed at prolonging survival and improving quality of life. This review illustrates their mechanisms of action and the possible future clinical applications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS . Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104: 439–444.

    Article  CAS  PubMed  Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  3. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454.

    Article  CAS  PubMed  Google Scholar 

  4. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A et al. New drugs for reatment of multiple myeloma. Lancet Oncol 2004; 5: 430–442.

    Article  CAS  PubMed  Google Scholar 

  5. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS . Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667.

    CAS  PubMed  Google Scholar 

  6. Shain KH, Landowski TH, Dalton WS . Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544–2553.

    Article  CAS  PubMed  Google Scholar 

  7. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB . Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci USA 1998; 95: 11107–11112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212–2221.

    CAS  PubMed  Google Scholar 

  9. Hideshima T, Nakamura N, Chauhan D, Anderson KC . Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991–6000.

    Article  CAS  PubMed  Google Scholar 

  10. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428–435.

    Article  CAS  PubMed  Google Scholar 

  11. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–1103.

    Article  CAS  PubMed  Google Scholar 

  12. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC . The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519–4527.

    Article  CAS  PubMed  Google Scholar 

  13. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673–5683.

    Article  CAS  PubMed  Google Scholar 

  14. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002; 1: 539–544.

    Article  CAS  PubMed  Google Scholar 

  15. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B . Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626–634.

    Article  CAS  PubMed  Google Scholar 

  16. Tu Y, Gardner A, Lichtenstein A . The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763–6770.

    CAS  PubMed  Google Scholar 

  17. Qiang Yw, Kopantzev E, Rudikoff S . Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138–4146.

    Article  CAS  PubMed  Google Scholar 

  18. Ge Nl, Rudikoff S . Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856–2861.

    CAS  PubMed  Google Scholar 

  19. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002; 62: 3876–3882.

    CAS  PubMed  Google Scholar 

  20. Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004; 90: 1076–1083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231–239.

    Article  CAS  PubMed  Google Scholar 

  22. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.

    Article  CAS  PubMed  Google Scholar 

  23. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941–2948.

    Article  CAS  PubMed  Google Scholar 

  24. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055–4062.

    Article  CAS  PubMed  Google Scholar 

  25. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 18: 1565–1571.

    Article  Google Scholar 

  26. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494.

    Article  CAS  PubMed  Google Scholar 

  27. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897–901.

    Article  CAS  PubMed  Google Scholar 

  28. Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al., Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404–408.

    CAS  PubMed  Google Scholar 

  29. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382.

    CAS  PubMed  Google Scholar 

  30. Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 408–414.

    CAS  PubMed  Google Scholar 

  31. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77.

    Article  CAS  PubMed  Google Scholar 

  32. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399–403.

    CAS  PubMed  Google Scholar 

  33. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991–995.

    Article  CAS  PubMed  Google Scholar 

  34. Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616.

    Article  CAS  PubMed  Google Scholar 

  35. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739.

    Article  CAS  PubMed  Google Scholar 

  36. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276.

    Article  CAS  PubMed  Google Scholar 

  37. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.

    Article  CAS  PubMed  Google Scholar 

  38. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  PubMed  Google Scholar 

  39. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779.

    Article  CAS  PubMed  Google Scholar 

  40. Palumbo A, Bertola A, Musto P, Pregno P, Bringhen S, Rus C et al. Oral melphalan, prednisone and thalidomide for multiple myeloma. Cancer, in press.

  41. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.

    Article  CAS  PubMed  Google Scholar 

  42. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.

    Article  CAS  PubMed  Google Scholar 

  43. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168–1171.

    Article  CAS  PubMed  Google Scholar 

  44. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067.

    Article  CAS  PubMed  Google Scholar 

  45. Richardson P . Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003; 29 (Suppl 1): 33–39.

    Article  CAS  PubMed  Google Scholar 

  46. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  PubMed  Google Scholar 

  47. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587–590.

    Article  CAS  PubMed  Google Scholar 

  48. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomid, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 725–762.

    Article  Google Scholar 

  49. Jagannath S, Durie BGM, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomid therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 7764–7783.

    Article  Google Scholar 

  50. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I . Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340: 1049–1052.

    Article  CAS  PubMed  Google Scholar 

  51. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664–670.

    Article  CAS  PubMed  Google Scholar 

  52. Berenson J . Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients – the American experience. Br J Clin Pract Suppl 1996; 87: 5–7.

    CAS  PubMed  Google Scholar 

  53. Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345–2350.

    Article  CAS  PubMed  Google Scholar 

  54. Borad MJ, Swift R, Berenson JR . Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005; 19: 154–156.

    Article  CAS  PubMed  Google Scholar 

  55. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC . Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712–3721.

    Article  CAS  PubMed  Google Scholar 

  56. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248–1252.

    Article  CAS  PubMed  Google Scholar 

  57. Ashcroft AJ, Davies FE, Morgan GJ . Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003; 4: 284–292.

    Article  CAS  PubMed  Google Scholar 

  58. Vanderkerken K, Asosingh K, Croucher P, Van Camp B . Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003; 194: 196–206.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisione di Ematologia dell'Università di Torino, Ospedale San Giovanni Battista, Torino, Italy

    B Bruno, L Giaccone, M Rotta & M Boccadoro

  2. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA

    K Anderson

Authors
  1. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Rotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Multiple Myeloma Research Foundation

Corresponding author

Correspondence to B Bruno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruno, B., Giaccone, L., Rotta, M. et al. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19, 1729–1738 (2005). https://doi.org/10.1038/sj.leu.2403905

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403905

Keywords

This article is cited by

Search

Advanced search

Quick links